Cargando…
(64)Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial
Breast cancers are most frequently oestrogen receptor (ER) and progesterone receptor (PR) positive and [(18)F]Fluorodeoxyglucose PET-CT (FDG) has lower sensitivity for these subtypes. The gastrin-releasing peptide receptor (GRPR) is overexpressed in ER+/PR+ breast cancers. This study assessed the sa...
Autores principales: | Wong, Keith, Sheehan-Dare, Gemma, Nguyen, Andrew, Ho, Bao, Liu, Victor, Lee, Jonathan, Brown, Lauren, Dear, Rachel, Chan, Lyn, Sharma, Shikha, Malaroda, Alessandra, Smith, Isabelle, Lim, Elgene, Emmett, Louise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316435/ https://www.ncbi.nlm.nih.gov/pubmed/35890071 http://dx.doi.org/10.3390/ph15070772 |
Ejemplares similares
-
First-in-Humans Evaluation of Safety and Dosimetry of (64)Cu-LLP2A for PET Imaging
por: Laforest, Richard, et al.
Publicado: (2023) -
Dosimetry Prediction for Clinical Translation of (64)Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression
por: Natarajan, Arutselvan, et al.
Publicado: (2018) -
Selection Criteria for Determination of Optimal Reconstruction Method for Cu-64 Trastuzumab Dosimetry on Siemens Inveon PET Scanner
por: Lee, Seonhwa, et al.
Publicado: (2019) -
Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [(64)Cu]copper PET/CT
por: Kjærgaard, Kristoffer, et al.
Publicado: (2020) -
Evolution of Bombesin Conjugates for Targeted PET Imaging of Tumors
por: Zhang, Hanwen, et al.
Publicado: (2012)